G-CSF: trials, targets and approvals

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 1	NCT06547112 Background	Oct 2024 → Jul 2025	plasma cell myeloma	Washington University School of Medicine	Completed	No outcome recorded

Date	Issuer	Release
2023-09-11	BioLineRx, Ltd.	BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma biolinerx.com ↗
2023-04-17	BioLineRx, Ltd.	BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma biolinerx.com ↗
2022-03-03	BioLineRx, Ltd.	BioLineRx Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization biolinerx.com ↗

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	G-CSF	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06547112 ↗
Route	Subcutaneous	“via subcutaneous injection” NCT06547112 ↗